MetaVia Inc. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025

Reuters

08/06

<a href="https://laohu8.com/S/MTVA">MetaVia Inc</a>. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025

MetaVia Inc. (Nasdaq: MTVA), a biotechnology company focused on cardiometabolic diseases, has announced an extension of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist targeting obesity. The trial's 48 mg multiple ascending dose cohort has been extended to 8 weeks, with a fifth weekly dose administered to the first patient. This extension aims to assess early efficacy, safety, and patient tolerability with longer-term exposure, and explore the non-titrated maximum tolerated dose. Previously reported data from the 32 mg dose showed promising results in weight loss and waist reduction with favorable safety profiles. Top-line data from the extended trial is anticipated in the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY44934) on August 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557437294"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557437294\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557437294?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557437294","market":"nz","top_or_hot":-1,"title":"MetaVia Inc. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MetaVia Inc. (Nasdaq: MTVA), a biotechnology company focused on cardiometabolic diseases, has announced an extension of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist targeting obesity. The trial's 48 mg multiple ascending dose cohort has been extended to 8 weeks, with a fifth weekly dose administered to the first patient. This extension aims to assess early efficacy, safety, and patient tolerability with longer-term exposure, and explore the non-titrated maximum tolerated dose. Previously reported data from the 32 mg dose showed promising results in weight loss and waist reduction with favorable safety profiles. Top-line data from the extended trial is anticipated in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY44934) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MetaVia Inc. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetaVia Inc. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-06 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MetaVia Inc. (Nasdaq: MTVA), a biotechnology company focused on cardiometabolic diseases, has announced an extension of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist targeting obesity. The trial's 48 mg multiple ascending dose cohort has been extended to 8 weeks, with a fifth weekly dose administered to the first patient. This extension aims to assess early efficacy, safety, and patient tolerability with longer-term exposure, and explore the non-titrated maximum tolerated dose. Previously reported data from the 32 mg dose showed promising results in weight loss and waist reduction with favorable safety profiles. Top-line data from the extended trial is anticipated in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY44934) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MTVA","symbol_name":"MetaVia Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL58HMgK:1","article_id":"2557437294","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557437294","pubTimestamp":1754483483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MetaVia Inc. , a biotechnology company focused on cardiometabolic diseases, has announced an extension of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist targeting obesity. The trial's 48 mg multiple ascending dose cohort has been extended to 8 weeks, with a fifth weekly dose administered to the first patient. This extension aims to assess early efficacy, safety, and patient tolerability with longer-term exposure, and explore the non-titrated maximum tolerated dose. Previously reported data from the 32 mg dose showed promising results in weight loss and waist reduction with favorable safety profiles. Top-line data from the extended trial is anticipated in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MTVA":"MetaVia Inc","BK4139":"生物科技"},"translate_title":"MetaVia Inc.宣布延长肥胖治疗DA-1726的1期临床试验，预计2025年第四季度获得顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTVA":0.9},"content_text":"MetaVia Inc. Announces Extension of Phase 1 Clinical Trial for Obesity Treatment DA-1726, Top-Line Data Expected Q4 2025\n    \n\n        MetaVia Inc. (Nasdaq: MTVA), a biotechnology company focused on cardiometabolic diseases, has announced an extension of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist targeting obesity. The trial's 48 mg multiple ascending dose cohort has been extended to 8 weeks, with a fifth weekly dose administered to the first patient. This extension aims to assess early efficacy, safety, and patient tolerability with longer-term exposure, and explore the non-titrated maximum tolerated dose. Previously reported data from the 32 mg dose showed promising results in weight loss and waist reduction with favorable safety profiles. Top-line data from the extended trial is anticipated in the fourth quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY44934) on August 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}